SBLOF (Shin Nippon Biomedical Laboratories) Forward PE Ratio: 14.94 (As of Jul. 06, 2026)


SBLOF Shin Nippon Biomedical Laboratories Ltd SBLOF
74 GF Score
Price $9.16
GF Value $13.86
! 5 Warning Signs
View Full Analysis

What is Shin Nippon Biomedical Laboratories Forward PE Ratio?

Shin Nippon Biomedical Laboratories SBLOF -2.13% 74 Forward PE Ratio is 14.94 as of Jul. 06, 2026. GuruFocus rates SBLOF with a GF Score™ of 74/100 and a GF Value™ of $13.86. The stock has 5 warning signs investors should review. Among 87 Medical Diagnostics & Research companies, Shin Nippon Biomedical Laboratories ranks better than 81.61% on this metric.

Shin Nippon Biomedical Laboratories's Forward PE Ratio for today is 14.94.

Shin Nippon Biomedical Laboratories's PE Ratio without NRI for today is 10.05.

Shin Nippon Biomedical Laboratories's PE Ratio (TTM) for today is 10.67.


Shin Nippon Biomedical Laboratories  (OTCPK:SBLOF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Shin Nippon Biomedical Laboratories Forward PE Ratio Related Terms


Shin Nippon Biomedical Laboratories Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Shin Nippon Biomedical Laboratories's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shin Nippon Biomedical Laboratories Forward PE Ratio Chart

Shin Nippon Biomedical Laboratories Annual Data
Trend 2025-03 2026-03
Forward PE Ratio
10.57 11.81

Shin Nippon Biomedical Laboratories Quarterly Data
2024-12 2025-03 2025-06 2025-09 2025-12 2026-03
Forward PE Ratio 21.11 10.57 9.89 12.75 11.57 11.81

SBLOF vs TMO, DHR, IDXX: Forward PE Ratio Comparison

For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shin Nippon Biomedical Laboratories Forward PE Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Shin Nippon Biomedical Laboratories's Forward PE Ratio falls into.


SBLOF
74GF Score
Shin Nippon Biomedical Laboratories Ltd SBLOF
Forward PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shin Nippon Biomedical Laboratories Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 14.94 mean?
Shin Nippon Biomedical Laboratories (SBLOF) has a Forward PE Ratio of 14.94 as of Jul. 06, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Shin Nippon Biomedical Laboratories and its competitors. According to the industry distribution chart, Shin Nippon Biomedical Laboratories ranks #16 out of 87 companies in the Medical Diagnostics & Research industry, placing it in the top 18.4%.
Is Shin Nippon Biomedical Laboratories' Forward PE Ratio too high?
Shin Nippon Biomedical Laboratories' current Forward PE Ratio is 14.94. The Medical Diagnostics & Research industry median Forward PE Ratio is 21.57. Shin Nippon Biomedical Laboratories' value of 14.94 is 30.7% below this industry median. Based on the distribution chart, Shin Nippon Biomedical Laboratories ranks #16 out of 87 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' Forward PE Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shin Nippon Biomedical Laboratories ranks #16 out of 87 companies for Forward PE Ratio. This places Shin Nippon Biomedical Laboratories in the top 18% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 21.57. Shin Nippon Biomedical Laboratories' value of 14.94 is 30.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Diagnostics & Research company?
The median Forward PE Ratio among Medical Diagnostics & Research companies is 21.57, based on 87 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shin Nippon Biomedical Laboratories's current Forward PE Ratio of 14.94 is 30.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Shin Nippon Biomedical Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median Forward PE Ratio is 21.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shin Nippon Biomedical Laboratories's current Forward PE Ratio is 14.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (SBLOF) has a current Forward PE Ratio of 14.94. The stock's GF Value™ is $13.86, compared to a current price of $9.16 — trading 33.9% below its estimated fair value. The current Forward PE Ratio is 14.94 and 30.7% below the Medical Diagnostics & Research industry median of 21.57. Shin Nippon Biomedical Laboratories' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (SBLOF), the current Forward PE Ratio is 14.94 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shin Nippon Biomedical Laboratories (SBLOF) Overvalued in 2026?

Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued. The current stock price of $9.16 is trading 33.9% below its estimated GF Value™ of $13.86.

Key valuation signals for SBLOF:

  • Forward PE Ratio: 14.94
  • GF Value™: $13.86 vs. price of $9.16 (33.9% below fair value)
  • GF Score™: 74/100 with 5 warning signs
  • Industry Position: 30.7% below the Medical Diagnostics & Research median (#16 of 87)

No single metric tells the full story. See the SBLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shin Nippon Biomedical Laboratories Business Description

Other Exchanges 2395:JapanYB3:Germany
Address 8-1 Akashi-cho, Tokyo, JPN
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
74GF Score

Get the complete analysis for SBLOF

Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.16
Price
$13.86
GF Value